Sevasemten not checked
Edgewise Therapeutics, Inc. · EDG-5506
FollowEvery change as it happens, and a Monday email
Trials
3 active
9 in total · 2 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Duchenne Muscular Dystrophy (2 trials), Becker Muscular Dystrophy
- Main trialPhase 2
- “The LYNX study is a 2-part, multicenter, Phase 2 study of safety, pharmacokinetics and biomarkers in children with Duchenne muscular dystrophy including a randomized, double-blind, placebo-controlled part A, followed by an open-label part B.”In the company’s words, NCT05540860 on ClinicalTrials.gov
- Other names
- EDG-5506
Other drugs for Duchenne Muscular Dystrophy
- AOC 1044Avidity Biosciences, Inc. · Phase 3
- GivinostatItalfarmaco · Phase 3
- SGT-003Solid Biosciences Inc. · Phase 3
- Zeleciment RostudirsenDyne Therapeutics · Phase 3
- DeramiocelCapricor Inc. · Phase 3
- DS-5141bDaiichi Sankyo · Phase 2
Coming up3
- Jan 2027Phase 2 trial completes · ClinicalTrials.gov
- Mar 2027Phase 2 trial completes · ClinicalTrials.gov
- Feb 2031Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials9
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | Jan 2027 | A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX) | |
| Phase 2Active, not recruiting | Mar 2027 | Phase 2 Study of EDG-5506 in Children and Adolescents With Duchenne Muscular Dystrophy Previously Treated With Gene Therapy | |
| Phase 2Enrolling by invitation | Feb 2031 | Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy | |
| Phase 2Completed | 7 Sep 2026 | Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON) | |
| Phase 1Completed | 15 Nov 2021 | A Study to Assess Safety, Tolerability, and PK of EDG-5506 in Healthy Volunteers and Becker Muscular Dystrophy Adults | |
| Phase 1Completed | 19 Aug 2022 | A Study to Assess the Feasibility of Non-invasive Dried Blood Sampling | |
| Phase 1Completed | 6 Apr 2023 | Absorption, Metabolism, Excretion and Absolute Bioavailability of EDG-5506 in Healthy Volunteers | |
| Phase 1Completed | 1 Mar 2024 | A Study of EDG-5506 in Adult Males With Becker Muscular Dystrophy | |
| Phase 1Completed | 22 Feb 2025 | A Study to Evaluate Effect of Verapamil and Food of Sevasemten in Healthy Volunteers |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026